. 2016 May 11;11:59. doi: 10.1186/s13023-016-0434-y

Table 2.

Budget impact of orphan drugs

Trade name	Active substance	Expenditure (EUR)						Share of total expenditure	Reimbursement category
Trade name	Active substance	2010	2011	2012	2013	2014	Total	Share of total expenditure	Reimbursement category
Atriance	Nelarabine	24 773					24 773	0.20 %	Individual reimbursement
Nexavar	Sorafenib	16 418	12 040	23 806	17 786	14 229	84 278	0.68 %
Revatio	Sildenafil	104 742	147 370	219 252	340 536	480 685	1 292 585	10.37 %
Volibris	Ambrisentan	52 172	87 744	142 289	128 058	163 633	573 897	4.60 %
Exjade	Deferasirox	5 726				7 329	13 055	0.10 %
Sprycel	Dasatinib	60 450					60 450	0.48 %
Wilzin	Zinc	1 317	169				1 486	0.01 %
Cystadane	Betaine	1 038	3 142	2 094	4 327	6 560	17 161	0.14 %
Diacomit	Stiripentol	6 696	8 940	14 354	11 424	16 947	58 360	0.47 %
Glivec	Imatinib		47 731	68 608			116 340	0.93 %
Arzerra	Ofatumumab		27 830				27 830	0.22 %
Mozobil	Plerixafor		12 796	25 592			38 389	0.31 %
Nplate	Romiplostim		13 687				13 687	0.11 %
Revolade	Eltrombopag		3 790				3 790	0.03 %
Tracleer	Bosentan					12 697	12 697	0.10 %
Glivec	Imatinib	1 373 374	1 481 110	1 252 280			4 106 764	32.94 %	List A (previously List C)
Sprycel	Dasatinib		202 997	296 703	412 538	524 119	1 436 357	11.52 %	List C
Tasigna	Nilotinib			149 561	275 615	285 964	711 140	5.70 %	List C
Wilzin	Zinc					1 534	1 534	0.01 %	List B
Elaprase	Idursulfase	418 275	501 228	596 232	681 408	707 619	2 904 762	23.30 %	CCUH program
Kuvan	Sapropterin			173 374	173 374	213 828	560 575	4.50 %
Cystadane	Betaine			6 265	6 265	6 416	18 945	0.15 %
Increlex	Mecasermin			94 257	93 557	93 820	281 634	2.26 %
Myozyme	Alglucosidase alpha					71 548	71 548	0.57 %
Votubia	Everolimus					34 802	34 802	0.28 %
All Orphan Drugs		2 064 981	2 550 574	3 064 669	2 144 887	2 641 727	12 466 838
Total Pharmaceutical Market		276 690 000	290 190 000	295 480 000	307 590 000	316 040 000	Average
Share of Total Pharmaceutical Market		0.75 %	0.88 %	1.04 %	0.70 %	0.84 %	0.84 %
Total Drug Reimbursement Budget		105 911 722	118 204 402	117 007 689	117 384 880	122 326 421	Average
Share of Total Drug Reimbursement		1.95 %	2.16 %	2.62 %	1.83 %	2.16 %	2.14 %